lenvatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4942	417716-92-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: E-7080 E 7080 lenvatinib lenvima ER-203492-00 E7080 lenvatinib mesylate lenvatinib mesilate	a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) Molecular weight: 426.86 Formula: C21H19ClN4O4 CLOGP: 3.05 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 115.57 ALOGS: -4.84 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

E-7080
E 7080
lenvatinib
lenvima
ER-203492-00
E7080
lenvatinib mesylate
lenvatinib mesilate

a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)

Molecular weight: 426.86
Formula: C21H19ClN4O4
CLOGP: 3.05
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 115.57
ALOGS: -4.84
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
18	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company
March 26, 2015	PMDA	Eisai Co., Ltd.
Feb. 13, 2015	FDA	EISAI INC
May 28, 2015	EMA	Eisai Europe Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertension	829.31	24.54	512	9391	210691	50384530
Malignant neoplasm progression	744.18	24.54	329	9574	67795	50527426
Proteinuria	527.43	24.54	175	9728	16422	50578799
Decreased appetite	387.91	24.54	317	9586	200606	50394615
Palmar-plantar erythrodysaesthesia syndrome	319.00	24.54	127	9776	19971	50575250
Hepatic encephalopathy	237.14	24.54	84	9819	9552	50585669
Diarrhoea	197.35	24.54	384	9519	588092	50007129
Platelet count decreased	152.94	24.54	139	9764	100587	50494634
Blood pressure increased	151.92	24.54	157	9746	132975	50462246
Hypothyroidism	130.61	24.54	82	9821	34043	50561178
Cholecystitis	98.50	24.54	50	9853	13821	50581400
Drug ineffective	95.62	24.54	22	9881	819311	49775910
Stomatitis	90.20	24.54	105	9798	101239	50493982
Tumour haemorrhage	88.95	24.54	25	9878	1330	50593891
Tracheal fistula	67.95	24.54	11	9892	32	50595189
Fatigue	67.84	24.54	295	9608	707306	49887915
Pneumothorax	67.29	24.54	39	9864	13995	50581226
Fistula	62.38	24.54	31	9872	8187	50587034
Dysphonia	61.50	24.54	55	9848	38837	50556384
Oral pain	51.07	24.54	41	9862	24992	50570229
Gastrointestinal perforation	50.78	24.54	20	9883	3041	50592180
Dehydration	48.63	24.54	98	9805	152351	50442870
Nephrotic syndrome	48.47	24.54	22	9881	4748	50590473
Arterial haemorrhage	47.69	24.54	16	9887	1541	50593680
Ascites	47.58	24.54	46	9857	35815	50559406
Blood thyroid stimulating hormone increased	46.29	24.54	23	9880	6069	50589152
Protein urine present	45.96	24.54	22	9881	5355	50589866
Condition aggravated	43.58	24.54	4	9899	297054	50298167
Weight decreased	40.90	24.54	115	9788	221130	50374091
Posterior reversible encephalopathy syndrome	40.52	24.54	29	9874	14899	50580322
Cerebral haemorrhage	40.29	24.54	37	9866	27015	50568206
Hepatic function abnormal	37.96	24.54	39	9864	32642	50562579
Vomiting	37.86	24.54	184	9719	460574	50134647
Malaise	37.47	24.54	147	9756	335385	50259836
Cholecystitis acute	37.42	24.54	21	9882	7085	50588136
Drug hypersensitivity	35.19	24.54	4	9899	251006	50344215
Epistaxis	34.66	24.54	52	9851	63902	50531319
Colitis	34.34	24.54	40	9863	38489	50556732
Oesophageal fistula	32.35	24.54	7	9896	123	50595098
Intestinal perforation	32.27	24.54	22	9881	10457	50584764
Thrombocytopenia	31.46	24.54	74	9829	127599	50467622
Tracheal haemorrhage	31.45	24.54	7	9896	141	50595080
Primary adrenal insufficiency	31.33	24.54	6	9897	55	50595166
Hypersensitivity	31.26	24.54	3	9900	215158	50380063
Immune-mediated hepatitis	30.53	24.54	10	9893	894	50594327
Hypertensive crisis	29.97	24.54	23	9880	13131	50582090
Nausea	28.01	24.54	234	9669	705164	49890057
Oesophageal perforation	27.24	24.54	7	9896	264	50594957
Weight increased	26.41	24.54	4	9899	201887	50393334
Ammonia increased	26.40	24.54	14	9889	4227	50590994
Swelling	26.23	24.54	4	9899	200868	50394353
Large intestine perforation	26.13	24.54	17	9886	7477	50587744
Oesophageal varices haemorrhage	25.40	24.54	9	9894	1021	50594200
Product use in unapproved indication	25.19	24.54	64	9839	115755	50479466
Off label use	24.86	24.54	34	9869	474392	50120829

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Decreased appetite	715.98	23.45	562	12896	144780	29416289
Hepatic encephalopathy	708.52	23.45	254	13204	12781	29548288
Malignant neoplasm progression	692.71	23.45	425	13033	73434	29487635
Proteinuria	510.70	23.45	211	13247	15593	29545476
Palmar-plantar erythrodysaesthesia syndrome	473.28	23.45	196	13262	14563	29546506
Hypertension	451.31	23.45	393	13065	116221	29444848
Diarrhoea	351.90	23.45	576	12882	332122	29228947
Hypothyroidism	233.18	23.45	123	13335	15783	29545286
Tumour haemorrhage	199.63	23.45	65	13393	2420	29558649
Liver carcinoma ruptured	174.05	23.45	34	13424	131	29560938
Fatigue	165.36	23.45	410	13048	316411	29244658
Blood pressure increased	143.25	23.45	172	13286	73631	29487438
Dysphonia	140.73	23.45	95	13363	19101	29541968
Ascites	114.59	23.45	110	13348	36509	29524560
Malaise	112.20	23.45	233	13225	159369	29401700
Oesophageal varices haemorrhage	111.14	23.45	43	13415	2659	29558410
Hepatic failure	97.32	23.45	94	13364	31418	29529651
Drug ineffective	95.70	23.45	24	13434	363146	29197923
Ammonia increased	88.27	23.45	41	13417	3990	29557079
Stomatitis	82.76	23.45	93	13365	37020	29524049
Cholecystitis	78.29	23.45	50	13408	9147	29551922
Pneumothorax	72.34	23.45	59	13399	15783	29545286
Blood bilirubin increased	70.60	23.45	82	13376	33811	29527258
Cholangitis	69.22	23.45	43	13415	7494	29553575
Oral pain	65.64	23.45	45	13413	9262	29551807
Dehydration	61.93	23.45	151	13307	114597	29446472
Hepatic function abnormal	60.98	23.45	82	13376	39177	29521892
Blood thyroid stimulating hormone increased	60.07	23.45	29	13429	3076	29557993
Tumour rupture	55.66	23.45	14	13444	200	29560869
Epistaxis	51.77	23.45	88	13370	51616	29509453
Drug interaction	48.18	23.45	15	13443	197370	29363699
Weight decreased	47.78	23.45	164	13294	150741	29410328
Toxicity to various agents	46.51	23.45	11	13447	173650	29387419
Tracheal fistula	45.83	23.45	10	13448	73	29560996
Portal vein thrombosis	43.98	23.45	24	13434	3285	29557784
Condition aggravated	43.94	23.45	7	13451	146288	29414781
Hyperammonaemia	43.80	23.45	29	13429	5634	29555435
Platelet count decreased	40.58	23.45	122	13336	104550	29456519
Off label use	37.83	23.45	49	13409	300751	29260318
Vomiting	36.84	23.45	192	13266	212068	29349001
Taste disorder	35.83	23.45	24	13434	4752	29556317
Cholecystitis acute	35.81	23.45	25	13433	5294	29555775
Gastrointestinal perforation	34.86	23.45	21	13437	3462	29557607
Thyroiditis	34.28	23.45	17	13441	1911	29559158
Tracheo-oesophageal fistula	33.52	23.45	11	13447	419	29560650
Immune-mediated hepatitis	31.78	23.45	15	13443	1512	29559557
Liver abscess	30.53	23.45	19	13439	3319	29557750
Neutropenia	30.38	23.45	11	13447	131700	29429369
Rhythm idioventricular	29.39	23.45	9	13449	273	29560796
Protein urine present	29.15	23.45	21	13437	4673	29556396
Liver disorder	26.14	23.45	46	13412	27703	29533366
Nausea	25.98	23.45	222	13236	289033	29272036
Protein induced by vitamin K absence or antagonist II increased	25.86	23.45	5	13453	18	29561051
Haemobilia	24.50	23.45	8	13450	300	29560769
Arterial haemorrhage	24.20	23.45	10	13448	734	29560335
Nephrotic syndrome	23.62	23.45	21	13437	6307	29554762

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1170.76	22.09	574	16205	112297	64369656
Hypertension	1026.93	22.09	704	16075	258557	64223396
Proteinuria	843.20	22.09	304	16475	27419	64454534
Decreased appetite	748.29	22.09	602	16177	280687	64201266
Hepatic encephalopathy	662.85	22.09	237	16542	20829	64461124
Palmar-plantar erythrodysaesthesia syndrome	611.45	22.09	243	16536	28576	64453377
Diarrhoea	315.93	22.09	622	16157	722082	63759871
Tumour haemorrhage	270.38	22.09	78	16701	3415	64478538
Hypothyroidism	267.67	22.09	153	16626	40304	64441649
Drug ineffective	156.85	22.09	18	16761	840229	63641724
Pneumothorax	152.91	22.09	89	16690	24209	64457744
Cholecystitis	145.37	22.09	80	16699	19556	64462397
Liver carcinoma ruptured	139.55	22.09	26	16753	146	64481807
Platelet count decreased	135.30	22.09	191	16588	167520	64314433
Ascites	127.32	22.09	115	16664	61886	64420067
Oesophageal varices haemorrhage	110.85	22.09	40	16739	3589	64478364
Blood pressure increased	108.50	22.09	175	16604	172377	64309576
Tracheal fistula	102.86	22.09	19	16760	101	64481852
Malaise	98.82	22.09	275	16504	395972	64085981
Dysphonia	93.17	22.09	85	16694	46297	64435656
Hepatic function abnormal	90.40	22.09	97	16682	64216	64417737
Blood bilirubin increased	86.57	22.09	90	16689	57463	64424490
Dehydration	78.86	22.09	174	16605	216589	64265364
Blood thyroid stimulating hormone increased	76.09	22.09	38	16741	7616	64474337
Cholecystitis acute	75.14	22.09	43	16736	11317	64470636
Tracheo-oesophageal fistula	70.15	22.09	18	16761	503	64481450
Hepatic failure	69.95	22.09	79	16700	55315	64426638
Arterial haemorrhage	69.67	22.09	25	16754	2206	64479747
Nephrotic syndrome	68.11	22.09	38	16741	9529	64472424
Toxicity to various agents	67.03	22.09	8	16771	363505	64118448
Condition aggravated	66.73	22.09	9	16770	372417	64109536
Fistula	64.70	22.09	37	16742	9724	64472229
Stomatitis	64.53	22.09	108	16671	109497	64372456
Fatigue	63.12	22.09	370	16409	748360	63733593
Ammonia increased	61.67	22.09	32	16747	6945	64475008
Gastrointestinal perforation	60.10	22.09	29	16750	5395	64476558
Immune-mediated hepatitis	59.78	22.09	23	16756	2466	64479487
Cholangitis	58.65	22.09	36	16743	10766	64471187
Hyperammonaemia	51.22	22.09	32	16747	9872	64472081
Portal vein thrombosis	50.26	22.09	25	16754	4966	64476987
Cerebral haemorrhage	49.96	22.09	64	16715	51026	64430927
Vomiting	47.35	22.09	274	16505	550843	63931110
Primary adrenal insufficiency	44.20	22.09	9	16770	85	64481868
Posterior reversible encephalopathy syndrome	44.01	22.09	41	16738	22905	64459048
Protein urine present	43.97	22.09	28	16751	8928	64473025
Hypertensive crisis	43.75	22.09	37	16742	18211	64463742
Drug interaction	43.37	22.09	20	16759	362063	64119890
Large intestine perforation	41.94	22.09	31	16748	12573	64469380
Epistaxis	41.68	22.09	84	16695	98047	64383906
Weight decreased	41.15	22.09	165	16614	285574	64196379
Haemoptysis	41.13	22.09	57	16722	48991	64432962
Weight increased	41.06	22.09	4	16775	213344	64268609
Hypersensitivity	39.67	22.09	3	16776	196449	64285504
Intestinal perforation	38.68	22.09	32	16747	15281	64466672
Drug hypersensitivity	37.59	22.09	8	16771	237807	64244146
Off label use	36.78	22.09	68	16711	632738	63849215
Tumour rupture	36.78	22.09	10	16769	351	64481602
Pneumonitis	34.22	22.09	53	16726	50312	64431641
Fall	34.02	22.09	35	16744	416791	64065162
Tumour lysis syndrome	33.98	22.09	33	16746	19407	64462546
Oesophageal perforation	33.77	22.09	12	16767	1029	64480924
Oesophageal fistula	33.49	22.09	9	16770	302	64481651
Cerebral infarction	33.37	22.09	47	16732	40997	64440956
Thyroiditis	33.12	22.09	17	16762	3607	64478346
Upper gastrointestinal haemorrhage	32.68	22.09	43	16736	35177	64446776
Drug intolerance	32.56	22.09	5	16774	187987	64293966
Pyrexia	32.38	22.09	252	16527	558392	63923561
Colitis	32.11	22.09	56	16723	58618	64423335
Product dose omission issue	29.86	22.09	7	16772	194740	64287213
Liver disorder	29.29	22.09	51	16728	53300	64428653
Pulmonary embolism	29.12	22.09	94	16685	146262	64335691
Rhythm idioventricular	28.87	22.09	9	16770	514	64481439
Cardiac failure	28.15	22.09	87	16692	132286	64349667
Oral pain	27.75	22.09	35	16744	27458	64454495
Sinusitis	27.39	22.09	3	16776	145925	64336028
Adrenal insufficiency	26.56	22.09	31	16748	22456	64459497
Abdominal pain	26.52	22.09	155	16624	312220	64169733
Interstitial lung disease	26.38	22.09	70	16709	97662	64384291
Small intestinal perforation	26.20	22.09	13	16766	2567	64479386
Overdose	25.97	22.09	5	16774	159561	64322392
Pancreatitis	25.26	22.09	51	16728	59556	64422397
Pain	25.15	22.09	68	16711	553443	63928510
Hyponatraemia	24.88	22.09	90	16689	148249	64333704
Liver abscess	24.66	22.09	16	16763	5264	64476689
Cholangitis acute	24.45	22.09	10	16769	1258	64480695
Renal impairment	24.44	22.09	84	16695	134933	64347020
Tracheal haemorrhage	23.57	22.09	8	16771	598	64481355
Hyperthyroidism	23.06	22.09	26	16753	18153	64463800
Cancer pain	22.63	22.09	14	16765	4243	64477710

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000020000	Receptor Tyrosine Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:62434	ALK inhibitor
CHEBI has role	CHEBI:63457	FGFR inhibitors
CHEBI has role	CHEBI:65207	vascular endothelial growth factor receptor inhibitors
CHEBI has role	CHEBI:71031	orphan drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Endometrial carcinoma progressing after chemotherapy	indication	254878006	DOID:2871
Follicular thyroid carcinoma	indication	255028004	DOID:3962
Papillary thyroid carcinoma	indication	255029007	DOID:3969
Renal cell carcinoma	indication	702391001	DOID:4450
Thymic carcinoma	indication	722670005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.09	acidic
pKa2	12.74	acidic
pKa3	13.02	acidic
pKa4	4.67	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	9006256	July 27, 2027	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	9006256	July 27, 2027	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Feb. 13, 2022	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Feb. 13, 2022	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Sept. 17, 2022	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Sept. 17, 2022	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	July 21, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	July 21, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 10, 2024	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 10, 2024	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Dec. 19, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Dec. 19, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 15, 2025	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 15, 2025	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN	INHIBITOR	Ki	8.82	CHEMBL	DRUG LABEL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN	INHIBITOR	IC50	7	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	IC50	7.66	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	IC50	8.40	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	IC50	8.28	SCIENTIFIC LITERATURE	DRUG LABEL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN	INHIBITOR	IC50	7.29	SCIENTIFIC LITERATURE	DRUG LABEL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN	INHIBITOR	IC50	7.34	SCIENTIFIC LITERATURE	DRUG LABEL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	5.51	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	7.96	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	5.41	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.34	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		Kd	6.76	CHEMBL
MAP kinase-activated protein kinase 2	Kinase	P49137	MAPK2_HUMAN		Kd	7.20	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.66	CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone]	Enzyme	P16083	NQO2_HUMAN		Kd	5.82	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	6.24	CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1	Kinase	O75460	ERN1_HUMAN		Kd	5.65	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	5.54	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		Kd	5.55	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	6.50	CHEMBL
Mitogen-activated protein kinase kinase kinase 6	Kinase	O95382	M3K6_HUMAN		Kd	5.80	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN	INHIBITOR	IC50	7.41	SCIENTIFIC LITERATURE
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	IC50	5.19	SCIENTIFIC LITERATURE
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		Kd	5.75	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	5.42	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.88	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	5.39	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	6.10	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	6.25	CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	6.66	CHEMBL

External reference:

ID	Source
EE083865G2	UNII
D09919	KEGG_DRUG
4034239	VUID
N0000191429	NUI
857890-39-2	SECONDARY_CAS_RN
4034239	VANDF
C2986924	UMLSCUI
CHEBI:85994	CHEBI
LEV	PDB_CHEM_ID
CHEMBL1289601	ChEMBL_ID
9823820	PUBCHEM_CID
DB09078	DRUGBANK_ID
CHEMBL2105704	ChEMBL_ID
9361	INN_ID
C531958	MESH_SUPPLEMENTAL_RECORD_UI
7426	IUPHAR_LIGAND_ID
1603296	RXNORM
232716	MMSL
294829	MMSL
294831	MMSL
30895	MMSL
d08346	MMSL
714108002	SNOMEDCT_US
714109005	SNOMEDCT_US
735068004	SNOMEDCT_US
015899	NDDF
015900	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-704	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-704	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-708	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-708	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-710	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-710	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-712	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-712	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-720	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-720	CAPSULE	10 mg	ORAL	NDA	32 sections